文献库搜索 | GeneLibs

Chu(HH),Liu(FY),Wang(CC),Lin(MC),Lai(CH) Case Rep Oncol None

...BRCA2 heterozygous deletion), which was controlled by adjuvant radiotherapy combined with nivolumab and nab-paclitaxel, ...

Singh(A),Bu(S),Perron(AV),Bhatt(KS),Sandhu... J Hypertens 2026-10-01

...BRCA2 ) are well known to increase the risk of breast and ovarian cancers. Emerging evidence indicates that BRCA2 mutati...

Morozumi(K),Nakamura(Y),Oikawa(M),Iwamura(... Urol Oncol 2026-09-00

...BRCA2 alterations have been associated with aggressive disease, the clinical significance of BRCA2 protein expression fo...

Svirsky(R),Sonnenfeld(B),Kedar(I),Linial(M... Genet Med Open None

...BRCA2, ATM, NF1, and MSH6), and 21 (7.2%) had risk allele variants. One-third (33%) of the disease-causing or likely dis...

Sherigar(P),Kedlaya Herga(S),Pai(A),Mailan... Cancer Med 2026-07-00

...BRCA2 genes. Yet, the role of other cancer susceptibility genes highlights the genetic etiology of HBOC as complex, thus...

Anjum(RS),Takabe(K) World J Oncol 2026-08-00

...BRCA2)-mutant tumors, impaired RAD51 loading produces profound sensitivity to DNA-damaging agents. However, accumulating...

Gunuganti(A),Barve(V),Kelly(WJ),Gunuganti(... Front Oncol None

...BRCA2 and was negative for Rb1 and TP53. He achieved complete systemic response following platinum-based chemoradiothera...

van Wyk(C),Abdulrahim(R),Crous(I),Al Saegh... Case Rep Genet None

...BRCA2-associated PCa in Omani patients, focusing on family communication, risk awareness, and cascade testing uptake. Th...

Mohan(A),Griffith(KA),Goff(LW),Crysler(O),... Clin Cancer Res 2026-07-23

...BRCA2 (n = 3), ATM (2), FANCA (1), IDH1 (3)). 4-month PFS rate was 54.8% (95% confidence intervals (CI), 36.0-72.7) in a...

Karakaya(G) Front Oncol None

...BRCA2 frameshift mutation with somatic loss of heterozygosity. Based on this molecular profile, off-label olaparib thera...